Summary: A new study links low maternal thyroxine levels during pregnancy to a higher risk of schizophrenia in offspring.
Source: Elsevier
Researchers report that low free thyroxine levels during early to mid-gestation are associated with increased odds of schizophrenia in children.
Low circulating free thyroxine during pregnancy—referred to as hypothyroxinemia—has previously been tied to altered brain development and cognitive problems. It is also linked to preterm birth, which itself is a known risk factor for schizophrenia. A recent case-control study published in Biological Psychiatry investigated whether maternal hypothyroxinemia during pregnancy is associated with schizophrenia in offspring.
The research, led by senior author Dr. Alan Brown of Columbia University and colleagues, analyzed archived prenatal serum samples collected in Finland as part of the Finnish Maternity Cohort. The investigators compared free thyroxine levels from 1,010 mothers of individuals diagnosed with schizophrenia to 1,010 matched control mothers. Serum samples were obtained in the first and early second trimesters, a critical window for fetal brain development. Case status was established using comprehensive national registries of medical and psychiatric diagnoses.
Results showed that 11.8% of people with schizophrenia had been exposed in utero to maternal hypothyroxinemia, compared with 8.6% of matched controls. This difference was statistically significant and corresponded to increased odds of schizophrenia among offspring of mothers with low free thyroxine levels. The association persisted after adjusting for important confounders strongly related to schizophrenia risk, including maternal psychiatric history and maternal smoking during pregnancy.
Adjusting for preterm birth weakened the relationship between hypothyroxinemia and schizophrenia, a finding consistent with the possibility that preterm delivery may partially mediate the increased risk. However, the study did not establish a causal mechanism and authors emphasize that further research is needed to determine how maternal thyroid hormone insufficiency might disrupt fetal brain development and contribute to later psychiatric illness.
First author Dr. David Gyllenberg of the University of Turku highlighted how the study connects clinical findings to a larger body of animal and human literature showing that maternal thyroid hormone insufficiency can alter offspring brain structure and function. Dr. Gyllenberg conducted much of the work while a visiting scholar at Columbia University.
Dr. Alan Brown noted that the study adds to evidence that both environmental and genetic maternal influences can shape neurodevelopmental risk. He cautioned that independent replication is necessary before drawing definitive clinical conclusions, but also emphasized that the study’s large, population-based design strengthens the credibility of the observed association.
The investigators also point out that the association may not be exclusive to schizophrenia. Maternal hypothyroxinemia during pregnancy could plausibly affect risk for a range of neurodevelopmental disorders, including bipolar disorder and autism spectrum disorders, and merits broader investigation.
From a clinical perspective, the study raises the possibility of preventive intervention. As noted by the journal editor, maternal hypothyroidism and related thyroid deficiencies are diagnosable and treatable conditions. If future research confirms a causal link between low maternal free thyroxine and offspring schizophrenia risk, screening and timely management of thyroid function in pregnancy could have important public health implications. Nevertheless, the authors stress that further translational work—especially experimental and animal studies—will be needed to identify the molecular and cellular pathways by which prenatal thyroid hormone insufficiency affects brain development.
The study used the Finnish Prenatal Study of Schizophrenia, a nested case-control design drawing on archived maternal sera from a national birth cohort initiated in 1983. Maternal serum free thyroxine and, in most samples, thyroid-stimulating hormone were measured prospectively. Case-control pairs were matched on sex, date of birth, and residence at the time of case onset. Statistical analyses adjusted for maternal psychiatric history, province of birth, and maternal smoking during pregnancy. Full author affiliations and disclosures are reported in the original publication.
Hypothyroxinemia During Gestation and Offspring Schizophrenia in a National Birth Cohort
Background: Animal and human studies indicate that thyroid hormone deficiency during early gestation can alter brain development. Given that schizophrenia is associated with prenatal brain insults and early cognitive deficits, the authors tested whether maternal serologic thyroid deficiency in early to mid-gestation is associated with schizophrenia in offspring.
Methods: Using a large Finnish birth cohort with archived maternal sera, the investigators identified offspring diagnosed with schizophrenia and matched them 1:1 to comparison subjects. Free thyroxine was measured in 1,010 case-control pairs; thyroid-stimulating hormone was measured in 948 pairs.
Results: Maternal hypothyroxinemia (free thyroxine at or below the 10th percentile with normal thyroid-stimulating hormone) was associated with higher odds of offspring schizophrenia (adjusted odds ratio approximately 1.7). The association remained significant after controlling for maternal psychiatric history, region of birth, and maternal smoking.
Conclusions: Prospectively documented hypothyroxinemia during early to mid-gestation was associated with increased odds of schizophrenia in offspring in a national birth cohort. These findings support further translational and mechanistic studies of how prenatal thyroid insufficiency may contribute to neurodevelopmental disorders.